Fulvestrant ('Faslodex'): current and future role in breast cancer management.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72645
Title:
Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Fulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.
Affiliation:
Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
Fulvestrant ('Faslodex'): current and future role in breast cancer management. 2006, 57 (3):265-73 Crit. Rev. Oncol. Hematol.
Journal:
Critical Reviews in Oncology/Hematology
Issue Date:
Mar-2006
URI:
http://hdl.handle.net/10541/72645
DOI:
10.1016/j.critrevonc.2005.08.001
PubMed ID:
16473018
Type:
Article
Language:
en
ISSN:
1040-8428
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-07-06T16:36:34Z-
dc.date.available2009-07-06T16:36:34Z-
dc.date.issued2006-03-
dc.identifier.citationFulvestrant ('Faslodex'): current and future role in breast cancer management. 2006, 57 (3):265-73 Crit. Rev. Oncol. Hematol.en
dc.identifier.issn1040-8428-
dc.identifier.pmid16473018-
dc.identifier.doi10.1016/j.critrevonc.2005.08.001-
dc.identifier.urihttp://hdl.handle.net/10541/72645-
dc.description.abstractFulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshAromatase-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials, Phase III as Topic-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshEstradiol-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshPostmenopause-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshReceptors, Somatotropin-
dc.subject.meshSignal Transduction-
dc.titleFulvestrant ('Faslodex'): current and future role in breast cancer management.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.